Novartis Strengthens Radiopharmaceutical Portfolio with $745M Deal with Ratio Therapeutics Targeting SSTR2

The partnership between Novartis and Ratio Therapeutics is centered around a $745 million agreement aimed at advancing the development of radiopharmaceuticals targeting the somatostatin receptor 2 (SSTR2). The collaboration involves leveraging Ratio's innovative radioligand technology to create specialized treatments that address tumors expressing SSTR2, which are found in cancers like neuroendocrine tumors and breast cancer[1][2]. Initially, the companies will jointly select a development candidate, with Novartis subsequently managing the further development, manufacturing, and commercialization processes. This agreement highlights Novartis' strategic focus on enhancing its oncological portfolio by employing cutting-edge radiopharmaceutical technology to offer more effective treatment options[2].